The Alliance for Regenerative Medicine Applauds New Rule From the Centers for Medicare & Medicaid Services Promoting Access to Innovative Therapies

September 2, 2020

Washington, DC

The Alliance for Regenerative Medicine (ARM) applauds the Centers for Medicare and Medicaid Services’ (CMS) decision to finalize a new diagnosis-related group (DRG) for chimeric antigen receptor T cell (CAR-T) therapies in their FY21 Inpatient Prospective Payment System (IPPS) rule. This is a crucial step forward for patient access to life-changing therapies, and the result of multi-year collaboration among ARM, its members, regulators, and a diverse group of other stakeholders.


FDA's Peter Marks Reiterates the Agency's Continued Commitment to Gene Therapy in Meeting With ARM's Executive Committee

August 27, 2020

Washington, DC

In a videoconference Thursday with the Executive Committee of the Alliance for Regenerative Medicine (ARM), the FDA’s Dr. Peter Marks reiterated the agency’s continued commitment to gene therapy, and explained that there have been no changes to FDA’s policies or approaches to gene therapies. The FDA remains focused on safety and efficacy in its evaluations of potentially transformative cell and gene therapies.


New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19

August 6, 2020

Washington, DC

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, “Innovation in the Time of COVID-19.” The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.


Alliance for Regenerative Medicine Calls for Multi-Stakeholder Pan-European Initiative to Fast-Track Real World Evidence in Support of Patient Access to Advanced Therapies

July 29, 2020

WASHINGTON, DC and BRUSSELS, BELGIUM